Lion Biotechnologies Inc. (NASDAQ:LBIO) was down 4.3% on Tuesday . The company traded as low as $7.76 and last traded at $7.78, with a volume of 289,437 shares changing hands. The stock had previously closed at $8.13.

Several research analysts have recently commented on LBIO shares. Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Saturday, June 4th. FBR & Co reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Tuesday, May 10th. Zacks Investment Research raised Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Wednesday, May 4th. Roth Capital reissued a “buy” rating and issued a $15.00 price target on shares of Lion Biotechnologies in a research report on Saturday, July 9th. Finally, SunTrust Banks Inc. lowered Lion Biotechnologies from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $37.00 to $30.50 in a research report on Monday, June 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $19.17.

The firm’s market cap is $377.73 million. The firm has a 50-day moving average of $7.87 and a 200 day moving average of $6.10.

Lion Biotechnologies (NASDAQ:LBIO) last issued its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. Analysts predict that Lion Biotechnologies Inc. will post ($0.73) earnings per share for the current year.

Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.